BioCentury
ARTICLE | Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

December 18, 2017 11:55 PM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an immunotherapeutic consisting of four synthetic long peptides from E6 transforming protein (HpV16gp1) and nine synthetic long peptides from E7 transforming protein (HpV16gp2) of the HPV type 16 virus.

Regeneron Director of Corporate Communications Alexandra Bowie said the partners plan to conduct two studies -- one in cervical cancer and the other in HPV16-positive head and neck cancer. Bowie and ISA Chief Business Officer Gerben Moolhuizen declined to disclose the phase of the trials. Moolhuizen said the trials "could potentially lead to registration."...

BCIQ Target Profiles

PD1